United Services Automobile Association Trims Holdings in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

United Services Automobile Association lessened its stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 3.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 302,743 shares of the company’s stock after selling 9,352 shares during the period. United Services Automobile Association owned about 0.57% of Rani Therapeutics worth $654,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in RANI. Marshall Wace LLP bought a new position in Rani Therapeutics during the 2nd quarter worth approximately $81,000. King Luther Capital Management Corp lifted its stake in Rani Therapeutics by 44.5% during the third quarter. King Luther Capital Management Corp now owns 81,129 shares of the company’s stock worth $175,000 after purchasing an additional 25,000 shares during the last quarter. Stifel Financial Corp boosted its holdings in Rani Therapeutics by 100.4% in the third quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock worth $583,000 after purchasing an additional 135,148 shares during the period. Finally, Vanguard Group Inc. increased its stake in Rani Therapeutics by 2.5% during the first quarter. Vanguard Group Inc. now owns 685,303 shares of the company’s stock valued at $2,131,000 after purchasing an additional 16,956 shares during the last quarter. 30.19% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Rani Therapeutics

In other Rani Therapeutics news, major shareholder South Cone Investments Limited sold 3,829,360 shares of Rani Therapeutics stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $2.65, for a total transaction of $10,147,804.00. Following the sale, the insider now owns 8,302,194 shares of the company’s stock, valued at $22,000,814.10. The trade was a 31.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 53.30% of the stock is currently owned by company insiders.

Rani Therapeutics Trading Up 4.3 %

Shares of RANI opened at $1.93 on Monday. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. Rani Therapeutics Holdings, Inc. has a 1 year low of $1.85 and a 1 year high of $8.75. The firm has a fifty day moving average of $2.28 and a 200-day moving average of $2.95.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Rani Therapeutics in a report on Tuesday, November 19th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Rani Therapeutics presently has an average rating of “Buy” and an average target price of $11.71.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.